Kabadi, U.M. (2002) United Kingdom Prospective Diabetes Study: A Different Perspective. Endocrine Practice, 8, 61-64.
http://dx.doi.org/10.4158/EP.8.1.61

has been cited by the following article:

• TITLE: Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!

  AUTHORS: Udaya M. Kabadi

  KEYWORDS: Review Paper

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.6 No.2, April 20, 2016

  ABSTRACT: It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.